MedTrace Logo

Telithromycin in Acute Exacerbation of Chronic Bronchitis

NCT00288223 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2009-12-09

No results posted yet for this study

Summary

Study objectives:

* to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.
* to assess the long-term clinical efficacy of telithromycin by telephone at D25-D35 (V3)
* to assess the safety of telithromycin

Conditions

  • Bronchitis, Chronic

Interventions

DRUG

Telithromycin

one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.

Sponsors & Collaborators

Principal Investigators

  • Edibe Taylan · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288223 on ClinicalTrials.gov